azetukalner

Azetukalner is a novel, potent small-molecule Kv7 (KCNQ) potassium channel opener being developed primarily for the treatment of epilepsy—including focal onset seizures and primary generalized tonic-clonic seizures—as well as major depressive disorder (MDD) and potentially other neurological disorders. It acts by opening Kv7.2/7.3 potassium channels in neurons to stabilize membrane potential and reduce neuronal hyperexcitability. Azetukalner has demonstrated dose-dependent reductions in seizure frequency in phase 2b and ongoing phase 3 trials for epilepsy, with sustained efficacy and tolerability observed over long-term open-label extension studies. In MDD clinical trials, it showed rapid-onset antidepressant effects but did not meet the primary endpoint at week 6; however, clinically meaningful improvements were observed at earlier time points. The drug is administered orally once daily with food[1][2][3][4][5][6].

Brand names

azetukalner

Other names

azetukalner